<DOC>
	<DOC>NCT01143818</DOC>
	<brief_summary>Observational study with AndroGel®, Testosterone 1% gel therapy (ESPRIT) in hypogonadal men in the community over 6 months.</brief_summary>
	<brief_title>ESPRIT Study in Hypogonadal Men</brief_title>
	<detailed_description>The objective of this study was to evaluate the efficacy and safety of AndroGel (testosterone gel) 1% following administration in community dwelling men with hypogonadism. The percent change from baseline to Month 6 in aging male symptom (AMS) assessment was the primary endpoint. Secondary endpoints were changes from baseline to Month 6 in International Index of Erectile Dysfunction (IIEF), Multidimensional Fatigue Inventory (MFI), and body mass index (BMI) assessments.</detailed_description>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Inclusion Criteria 1. Male patients &gt;= 18 years of age 2. Hypogonadism not previously treated with testosterone 3. Testosterone deficiency confirmed clinically and biochemically 4. Being prescribed AndroGel® 1% in accordance with the local summary of product characteristics Exclusion Criteria 1. According to the contraindications, 2. Unwilling or unable to sign informed consent form</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Male hypogonadism</keyword>
</DOC>